


IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-18 (Cancelled).


Claim 19 (New): A compound of the formula:



wherein R<sup>1</sup> and R<sup>2</sup> are taken together to form butenylene condensed with benzene,

X is CH,

Y is -NH-,



R<sup>3</sup> is phenyl substituted with halogen, and

the indan ring to form by taking together R<sup>1</sup>, R<sup>2</sup> and X is substituted by -Y-Q-R<sup>3</sup> at the 2-position.

Claim 20 (New): The compound of claim 19, wherein R<sup>3</sup> is phenyl substituted with fluorine.

Claim 21 (New): A composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier or excipient.

Claim 22 (New): A method for the treatment of amnesia, dementia, senile dementia, Alzheimer's dementia, dementia associated with various diseases including cerebral vascular dementia, cerebral post-traumatic dementia, dementia due to brain tumor, dementia due to chronic subdural hematoma, dementia due to normal pressure hydrocephalus, post-meningitis dementia, Parkinson's disease type dementia, schizophrenia, depression, stroke, head injury, nicotine withdrawal, spinal cord injury, anxiety, pollakiuria, incontinence of urine, myotonic dystrophy, attention deficit hyperactivity disorder, excessive daytime sleepiness (narcolepsy), Parkinson's disease or autism, comprising administering an effective amount of the compound of claim 19 to a subject in need thereof.


Claim 23 (New): The method of claim 22, wherein said effective amount ranges from 0.1 mg/body to 1,000 mg/body.

Claim 24 (New): A method for the treatment of schizophrenia which comprises administering an effective amount of the compound of Claim 19 to a subject in need thereof.

Claim 25 (New): A method for the treatment of amnesia which comprises administering an effective amount of the compound of Claim 19 to a subject in need thereof.

Claim 26 (New): A method for the treatment of dementia, senile dementia or Alzheimer's dementia which comprises administering an effective amount of the compound of Claim 19 to a subject in need thereof.

Claim 27 (New) An isolated or purified solvate of a compound of the formula:



wherein R<sup>1</sup> and R<sup>2</sup> are taken together to form butenylene condensed with benzene,

X is CH,

Y is -NH-,

Q is  $\begin{array}{c} O \\ || \\ -C- \end{array}$ ,

R<sup>3</sup> is phenyl substituted with halogen, and

the indan ring to form by taking together R<sup>1</sup>, R<sup>2</sup> and X is substituted by -Y-Q-R<sup>3</sup> at the 2-position.

Claim 28 (New): The solvate of claim 27, which is an enclosure compound.

Claim 29 (New): The solvate of claim 27, which is a hydrate or an ethanolate.

Claim 30 (New): The solvate of claim 27, wherein in said compound R<sup>3</sup> is phenyl substituted with fluorine.

Claim 31 (New): A composition comprising the solvate of claim 27 and a pharmaceutically acceptable carrier or excipient.

Claim 32 (New): A method for the treatment of amnesia, dementia, senile dementia, Alzheimer's dementia, dementia associated with various diseases including cerebral vascular

dementia, cerebral post-traumatic dementia, dementia due to brain tumor, dementia due to chronic subdural hematoma, dementia due to normal pressure hydrocephalus, post-meningitis dementia, Parkinson's disease type dementia, schizophrenia, depression, stroke, head injury, nicotine withdrawal, spinal cord injury, anxiety, pollakiuria, incontinence of urine, myotonic dystrophy, attention deficit hyperactivity disorder, excessive daytime sleepiness (narcolepsy), Parkinson's disease or autism, comprising administering an effective amount of the solvate of claim 27 to a subject in need thereof.

Claim 33 (New): The method of claim 32, wherein said effective amount ranges from 0.1 mg/body to 1,000 mg/body.

Claim 34 (New): A method for the treatment of schizophrenia which comprises administering an effective amount of the solvate of Claim 27 to a subject in need thereof.

Claim 35 (New): A method for the treatment of amnesia which comprises administering an effective amount of the solvate of Claim 27 to a subject in need thereof.

Claim 36 (New): A method for the treatment of dementia, senile dementia or Alzheimer's dementia which comprises administering an effective amount of the solvate of Claim 27 to a subject in need thereof.

Claim 37 (New): 4-fluoro-N-(indan-2-yl) benzamide.

Claim 38 (New): A pharmaceutical composition comprising the compound of claim 37, and a pharmaceutically acceptable carrier or excipient.

Claim 39 (New): A solvate of 4-fluoro-N-(indan-2-yl) benzamide.

Claim 40 (New): The solvate of claim 39 which is an enclosure compound.

Claim 41 (New): The solvate of claim 39 which is a hydrate or ethanolate.

Claim 42 (New): A pharmaceutical composition comprising the solvate of claim 39 and a pharmaceutically acceptable carrier or excipient.

Claim 43 (New): A method for the treatment of amnesia, dementia, senile dementia, Alzheimer's dementia, dementia associated with various diseases including cerebral vascular dementia, cerebral post-traumatic dementia, dementia due to brain tumor, dementia due to chronic subdural hematoma, dementia due to normal pressure hydrocephalus, post-meningitis dementia, Parkinson's disease type dementia, schizophrenia, depression, stroke, head injury, nicotine withdrawal, spinal cord injury, anxiety, pollakiuria, incontinence of urine, myotonic dystrophy, attention deficit hyperactivity disorder, excessive daytime sleepiness (narcolepsy), Parkinson's disease or autism, comprising administering to a subject in need thereof an effective amount of 4-fluoro-N-(indan-2-yl) benzamide or a solvate thereof.


Claim 44 (New): The method of claim 43, wherein said effective amount ranges from 0.1 mg/body to 1,000 mg/body.

Claim 45 (New): The method of claim 43 comprising administering an effective amount of said compound or solvate thereof to a subject having schizophrenia.

Claim 46 (New): The method of claim 43 comprising administering an effective amount of said compound or solvate thereof to a subject having amnesia.

Claim 47 (New): The method of claim 43 comprising administering an effective amount of said compound or solvate thereof to a subject having dementia, senile dementia or Alzheimer's dementia.

Claim 48 (New): A process for preparing a compound of the formula:



wherein R<sup>1</sup> and R<sup>2</sup> are taken together to form butenylene condensed with benzene,

X is CH,

Y is -NH-,

Q is  $\begin{array}{c} \text{O} \\ \parallel \\ \text{-C-} \end{array}$ ,

R<sup>3</sup> is phenyl substituted with halogen, and

the indan ring to form by taking together R<sup>1</sup>, R<sup>2</sup> and X is substituted by -Y-Q-R<sup>3</sup> at the 2-position,

which comprises,


reacting a compound of the formula:



or its salt with a compound of the formula:



or its reactive derivative at the carboxy group or a salt thereof to provide a compound of the formula:



wherein in the above formulas,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$  and Q are each as defined above.

Claim 49 (New): The process of claim 48 further comprising forming a solvate of said compound of formula (I).